BeStock  

Absci Corp ABSI

US equityMarket cap rank #2985AI medical concept stocks
$7.51 −$0.65 (-7.97%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.61 +1.33%
Open$7.91
Prev close$8.16
Day range$7.44 – $8.14
Volume4.75M
Market cap$1.30B
P/E (TTM)–
Dividend yield–
Founded2011
CEOMr. Sean McClain
Employees140
HeadquartersVancouver, United States of America
Websitewww.absci.com

Revenue per employee

$18.7K$25.1K$31.5K$38.0KDec '21Dec '23Dec '25

140 employees as of 2025/FY (-10.8% YoY). Revenue per employee is total revenue divided by headcount — a rough productivity gauge, not a per-worker pay figure.

Management team

Sean McClain Chief Executive Officer and Director
Age 36 · Total comp. $3,686,615.00 · As of 21 Apr 2026
Background

Sean McClain is our Founder and has served as our Chief Executive Officer since August 2011, as a member of our board of directors since the formation of Absci Corporation in October 2020, and a managing member of our predecessor, Absci LLC, since inception. Mr. McClain previously served as a board member for the Oregon Translational Research and Development Institute (OTRADI), a non-profit biosciences-focused incubator, and Life Science Washington, a non-profit trade association. Mr. McClain holds a Bachelor of Science degree in Molecular and Cellular Biology from the University of Arizona.

Dr. Zachariah Jonasson, PhD Chief Financial Officer and Chief Business Officer
Age 53 · Total comp. $2,306,795.00 · As of 21 Apr 2026
Background

Zachariah Jonasson, Ph.D. has served as our Chief Financial Officer and Chief Business Officer since August 31, 2023. Prior to serving in these roles, Dr. Jonasson served as an independent member of our board of directors from October 2020 to December 2023 and on the board of directors of Absci LLC, the Company's predecessor, from April 2016 to October 2020. Previously, Dr. Jonasson served as Managing General Partner of Phoenix Venture Partners LLC (PVP), a venture capital firm based in San Mateo, CA that he co-founded in August 2010 and as Managing General Partner of Convergent Ventures, a seed-stage venture capital firm based in San Francisco, CA that he co-founded in April 2023. He currently serves as an Advisor to Convergent Ventures. Dr. Jonasson previously served as a director on the boards of L7 Informatics, Inc., Micropore, Inc., Xandar Kardian, Inc., Green Theme Technologies, Inc., and Crop Enhancement, Inc. until his departure from PVP on August 31, 2023. He previously served on the board of the Oregon Translational Research and Development Institute (OTRADI) and Oregon Bioscience Incubator (OBI) and has previously served on the Commercialization Council of the Oregon Nanoscience and Microtechnologies Institute (ONAMI), the Advisory Board for the Oregon Innovation Cluster (OIC), and the Advisory Board of the Life Sciences Institute at the University of British Columbia. Previously, Dr. Jonasson was a co-founder and Chief Executive Officer Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA, previously named ReForm Biologics, LLC) and a co-founder and VP of Business Development of Crop Enhancement, LLC. Earlier in his career, Dr. Jonasson was a General Partner and Kauffman Fellow at Seaflower Ventures, an early-stage venture capital firm investing in the biotechnology sector. Dr. Jonasson earned a Bachelor of Science from Georgetown University in the Honors Program in 1995 and an A.M. and Ph.D. from Harvard University in 2000 and 2003, respectively, where he was a Sackler Scholar. He has cotaught a marketing course at Harvard Business School as well as served as a Teaching Fellow at Harvard University. Prior to graduate school, Dr. Jonasson was a Research Associate at the Board of Governors of the Federal Reserve System.

Mary T. Szela Director
Age 62 · Total comp. $367,541.00 · As of 21 Apr 2026
Background

Mary Szela has served as a member of our board of directors since July 2025. Ms. Szela has served as CEO and President of TriSalus Life Sciences since January 2018. Prior to joining TriSalus, Ms. Szela served as CEO of Aegerion Pharmaceuticals, Inc., from 2016 through Aegerion's merger with QLT Inc. to form Novelion Therapeutics Inc., where, until 2017, she served as CEO. Prior to Novelion, she was CEO of Melinta Therapeutics, leading the company's revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus). Previously, Ms. Szela held progressive leadership roles at Abbott Laboratories including President of the company's $8 billion U.S. pharmaceutical business. She developed global brands such as Humira and served as Senior Vice President for global strategic marketing and services. Ms. Szela currently serves as a member of the Board of Directors for Kura Oncology, Prometheus Biosciences, Omega Therapeutics and Senda Biosciences. She received both her B.S. in Nursing and her MBA from the University of Illinois at Chicago.

Frans Van Van Houten, M.Sc. Chairman of the Board
Age 65 · Total comp. $269,034.00 · As of 21 Apr 2026
Background

Frans van Houten has served as a member of our board of directors since June 2023. Mr. van Houten has also served as an independent director of Novartis AG since February 2017, Castor EDC since May 2023, Synthesis Health Inc. since May 2023 and Affidea Group since January 2024. Mr. van Houten also currently serves as Chair of Graduate Entrepreneur, a start-up venture fund and ecosystem which he co-founded in January 2020. Previously, Mr. van Houten was the Chief Executive Officer and Chair of the Board of Management and Executive Committee of Royal Philips NV from March 2011 until October 2022. Mr. van Houten served as Chief Executive Officer for NXP Semiconductors NV from October 2004 until December 2008 and in various managerial positions at Royal Philips from 1986 until 2004. Mr. van Houten also served as Co-Chair of the World Economic Forum in 2017 and Co-Founder and Co-Chair of the Platform for Accelerating the Circular Economy (PACE). Mr. van Houten received MSc and bachelor's degrees in economics from Erasmus University in Rotterdam.

Professor Menelas Pangalos, PhD Independent Director
Age 59 · Total comp. $245,597.00 · As of 21 Apr 2026
Background

Prof Sir Menelas Pangalos, Ph.D. has served as a member of our board of directors since January 2024. Sir Pangalos also serves as a board member of Biogen Inc. Sir Pangalos previously served as AstraZeneca's Executive Vice-President of R&D BioPharmaceuticals from January 2019 to March 2024 and in various Executive Vice-President roles for AstraZeneca since 2010. Prior to joining AstraZeneca, Sir Pangalos held senior R&D roles, including Senior Vice President, at Pfizer, Wyeth Research and GlaxoSmithKline. In 2019, Sir Pangalos was awarded a knighthood from Her Majesty The Queen of the United Kingdom of Great Britain and Northern Ireland. Sir Pangalos holds Honorary Doctorates from Glasgow University and Imperial College, London, is a Fellow of the Royal Society, the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge. Sir Pangalos has taught as a Visiting Professor of Neuroscience at Kings College in the Wolfson Centre for Age-Related Diseases since 2005. Sir Pangalos was also an Adjunct Professor of Neuroscience from 2007 to 2010 at the Institute of Neurological Sciences at Penn University. Sir Pangalos received a Ph.D. in Neurochemistry and undergraduate degree in Biochemistry from the University of London.

Karen K. McGinnis, C.P.A. Independent Director
Age 59 · Total comp. $240,097.00 · As of 21 Apr 2026
Background

Karen McGinnis has served as a member of our board of directors since August 2020. Ms. McGinnis has also served as an independent director of Alphatec Holdings, Inc. since June 2019 and iRhythm Holdings, Inc. since July 2025. She previously served as an independent director of Sonendo, Inc. from October 2021 to March 2024, and Biosplice Therapeutics, Inc. from April 2021 until March 2023. Ms. McGinnis was Vice President and Chief Accounting Officer of Illumina, Inc. from November 2017 until her retirement in April 2021. Ms. McGinnis also served as the Chief Executive Officer and President of Mad Catz Interactive Inc. from February 2016 to March 2017, the Chief Financial Officer of Mad Catz Interactive Inc. from June 2013 to February 2016 and served as the Chief Accounting Officer of Cymer, Inc. from November 2009 to June 2013. Previously, Ms. McGinnis served as Chief Accounting Officer for Insight Enterprises, Inc., from September 2006 until March 2009, its Senior Vice President of Finance from 2001 through September 2006 and its Vice President of Finance from 2000 through 2001. From 1997 to 2000, she served as the Chief Financial Officer of Horizon. Prior to Horizon, Ms. McGinnis was employed by KPMG LLP from 1989 to 1997 and served as a Senior Assurance Manager. Ms. McGinnis is a Certified Public Accountant and received a bachelor's degree in accounting from the University of Oklahoma.

Daniel A. Rabinovitsj Independent Director
Age 61 · Total comp. $237,597.00 · As of 21 Apr 2026
Background

Daniel Rabinovitsj has served as a member of our board of directors since November 2022. Mr. Rabinovitsj has served as a Vice President of Meta, the parent company of Facebook, and Facebook since August 2018. Previously, Mr. Rabinovitsj served as Chief Operating Officer of Ruckus Wireless, Inc., a global supplier of advanced wireless systems for the mobile Internet infrastructure market, from October 2014 until its acquisition by ARRIS International plc in December 2017. From 2011 to September 2014, Mr. Rabinovitsj served as Senior Vice President of Qualcomm Atheros, Inc.'s wired and wireless networking and small cell infrastructure business. Prior to Qualcomm Atheros, Mr. Rabinovitsj served in a number of executive management positions at companies including Atheros Communications, NXP Semiconductors, ST Ericsson, and Silicon Labs. Mr. Rabinovitsj previously served as a board member of QuickLogic Corporation and a private company developing intellectual property based upon machine learning to improve communication and other systems. Mr. Rabinovitsj received an M.A. in Asian Studies and a B.A. in Philosophy from the University of Texas at Austin.

Joseph Sirosh, PhD Independent Director
Age 57 · Total comp. $216,014.00 · As of 21 Apr 2026
Background

Joseph Sirosh, Ph.D. has served as a member of our board of directors since January 2022. Dr. Sirosh is currently the CEO and President of CreatorsAGI Inc, and recently served as Vice President of Amazon's Alexa Shopping group from October 2022 to November 2023. Previously, Dr. Sirosh served as the Chief Technology Officer of Compass, Inc. from December 2018 to August 2022 and held various positions at the Microsoft Corporation from July 2013 to December 2018, including Chief Technology Officer of Artificial Intelligence. During his tenure at Microsoft, Dr. Sirosh led product and engineering teams with responsibility for the enterprise database, Big Data, and machine learning products. Prior to Microsoft, Dr. Sirosh served as a Vice President of Technology at Amazon.Com, Inc., from December 2004 to July 2013, where he built the machine learning and Transaction Risk Management teams. Dr. Sirosh holds a B. Tech in Computer Science and Engineering from the Indian Institute of Technology, Madras, and an M.S. in Computer Science and a Ph.D. in Neural Networks from the University of Texas at Austin.

Shelby J. Walker, J.D.,M.S. Chief Legal Officer
Age 51 · As of 21 Apr 2026
Background

Shelby Walker, JD, has served as our Chief Legal Officer since June 2024. She leads our legal team and oversees our legal affairs, business transactions, intellectual property, risk management, and compliance. Prior to joining us, Ms. Walker served as General Counsel and Corporate Secretary of Korro Bio, Inc. (Nasdaq: KRRO) from May 2023 to June 2024. Previously, she held senior leadership roles as Senior Vice President, Intellectual Property at CRISPR Therapeutics (Nasdaq: CRSP) from March 2018 to April 2023 and General Counsel at Ginkgo Bioworks, Inc. from May 2016 to March 2018. Ms. Walker holds a JD and LLM from UNH Franklin Pierce School of Law, dual MS degrees in Bioscience Regulatory Affairs and Biotechnology from Johns Hopkins University, and a BS degree in Biotechnology from Worcester Polytechnic Institute.

Todd Bedrick Chief Accounting Officer
As of 23 Mar 2026
Background

Todd Bedrick, Chief Accounting Officer, oversees the accounting and reporting, corporate tax, financial planning and analysis, acquisition integration and has managed multiple company-wide system implementations. Todd played a crucial role through the company's IPO. His prior experience includes being a senior audit manager at Ernst & Young and the Director of Technical Accounting at The Greenbrier Companies. Todd earned his BSBA in Accounting from the University of Arizona - Eller College of Management, he also holds an MS in Financial Analysis, received from Portland State University - School of Business.

Dr. Ransi Somaratne, M.D. Chief Medical Officer
As of 5 Mar 2026
Background

On March 3, 2026, the Company issued appointment of Ransi Somaratne, M.D., as the Company's Chief Medical Officer, effective as of March 3, 2026. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somaratne is a physician-scientist and seasoned biopharmaceutical executive who joins Absci from Vertex Pharmaceuticals, where he served as Senior Vice President of Clinical Development. He previously held various scientific leadership roles at BioMarin Pharmaceutical and Amgen. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somaratne is a physician-scientist and seasoned biopharmaceutical executive who joins Absci from Vertex Pharmaceuticals, where he served as Senior Vice President of Clinical Development. He previously held various scientific leadership roles at BioMarin Pharmaceutical and Amgen. A cardiologist and internist by training, Dr. Somaratne's career is defined by work on multiple pioneering clinical development programs, including the Hemophilia A gene therapy Roctavian, the development and global approvals of a PCSK9 inhibitor Repatha, and the development and approval of Journavx, the first NaV1.8 inhibitor approved for moderate to severe acute pain. He earned his Doctor of Medicine (MD) degree from Albany Medical College in Albany, NY, and also holds a Masters in Business Administration (MBA) from the University of North Carolina at Chapel Hill. He has co-authored over 30 papers in peer-reviewed medical journals, including the New England Journal of Medicine and the Journal of the American Medical Association.

From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.

Sectors & themes

Discussion

No comments yet — be the first to weigh in on ABSI.

Sign in to join the discussion.

Scroll to Top